News
8 July 2026
VHL, CRBN and emerging E3 ligases like DCAF: compare handles for your PROTAC program and run fluorescence-based binding assays with ready-to-use kits.
25 May 2026
Targeted protein degradation (TPD) has reshaped drug discovery by eliminating disease-driving proteins through the cell’s own degradation systems, rather than merely blocking their activity. PROTACs (bifunctional […]
15 April 2026
How dual GLP-1/GIP receptor agonists like tirzepatide work, their pharmacological advantages over single agonists, and preclinical assay strategies.
30 March 2026
Fluorescent ligands have become powerful tools for measuring receptor binding kinetics and residence time in GPCR drug discovery. Unlike traditional radioligand approaches, fluorescence-based methods enable real-time, […]
12 March 2026
Ligand binding assays for non-GPCR drug targets like Sigma receptors and E3 ligases.
6 February 2026
Improve reproducibility and accelerate GPCR drug discovery with automated high-content screening assays and smart data workflows.
4 February 2026
Time-resolved fluorescence improves pharmacophore characterization accuracy in biochemical assays for advanced drug discovery workflows.
23 December 2025
How high-content screening enables cannabinoid receptor research while avoiding controlled substance restrictions and improving assay scalability.
16 December 2025
High-content screening enables precise CB2 receptor binding analysis in preclinical research using advanced imaging, quantification, and assay tools.